Dianthus Therapeutics (NASDAQ:DNTH) Earns Buy Rating from Analysts at Citigroup

Citigroup started coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a report published on Friday morning, MarketBeat reports. The brokerage issued a buy rating and a $156.00 price objective on the stock.

Other analysts have also issued research reports about the company. HC Wainwright upped their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wedbush lifted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $126.92.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $108.10 on Friday. The stock has a market capitalization of $5.91 billion, a P/E ratio of -26.05 and a beta of 1.24. The company has a 50 day moving average price of $105.23 and a 200 day moving average price of $89.37. Dianthus Therapeutics has a fifty-two week low of $24.49 and a fifty-two week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. On average, research analysts forecast that Dianthus Therapeutics will post -3.83 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Simrat Randhawa sold 23,124 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the transaction, the executive vice president owned 4,000 shares in the company, valued at approximately $425,640. The trade was a 85.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the transaction, the chief executive officer directly owned 65,292 shares in the company, valued at $7,058,718.12. This trade represents a 71.77% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 283,678 shares of company stock worth $29,672,400. Corporate insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth about $27,000. First Horizon Corp acquired a new position in Dianthus Therapeutics in the first quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Dianthus Therapeutics in the fourth quarter valued at approximately $40,000. EFG International AG purchased a new position in Dianthus Therapeutics in the second quarter valued at approximately $49,000. Finally, Russell Investments Group Ltd. purchased a new position in Dianthus Therapeutics in the third quarter valued at approximately $64,000. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.